Aug 2026· Biochemical and Biophysical Research Communications - BBRC· Vol 834, pp.
154452
· 1 citation· 80 references
Medicine
TL;DR
A role for FAP in cardiac fibroblast activation is supported and its induction to altered ER-phagy-related proteostasis and ER stress is linked to altered ER-phagy-related proteostasis and ER stress.
Abstract
Dilated cardiomyopathy (DCM) is characterized by progressive myocardial fibrosis and extracellular matrix remodeling, which severely impair cardiac function. The endoplasmic reticulum (ER) is essential for collagen synthesis, but the role of ER-phagy, a selective autophagy pathway that maintains ER proteostasis, in pathological cardiac fibroblast activation remains unclear. We integrated single-cell RNA-seq, bulk RNA-seq, and ATAC-seq datasets from human cardiac tissue and cultured human and rat cardiac fibroblasts. Key findings were validated in TGF-β-treated primary neonatal rat cardiac fibroblasts using siRNA-mediated FAP silencing and autophagy-associated assays. Fibroblast activation was accompanied by reduced expression and promoter accessibility of selected ER-phagy-related genes. An FAP-high activated fibroblast population showed a lower ER-phagy-related transcriptional signature. Integrated regulon and promoter-motif analyses linked FAP induction to a SMAD3-centered, BET-sensitive transcriptional program associated with repression of a subset of ER-phagy genes. FAP silencing attenuated fibroblast activation and ER stress and was accompanied by restored expression of selected ER-phagy-related transcripts and changes in autophagy-associated markers. These findings support a role for FAP in cardiac fibroblast activation and link its induction to altered ER-phagy-related proteostasis and ER stress.
ERIO is a safe, effective natural flavonoid with promising preclinical efficacy, suggesting its potential clinical translation for myocardial fibrosis and offering new therapeutic targets to prevent heart failure progression.
Yu-Ting Liu, Yan Che, Yazhi Ding et al.· British Journal of Pharmacol...· 0 citations
Dysferlin is a stress-inducible antifibrotic regulator that limits maladaptive fibroblast differentiation and myocardial fibrosis, thereby representing a potential therapeutic target to attenuate adverse cardiac remodelling in HF.
I. Kocherova, Muriel Giger, A. Laimbacher et al.· bioRxiv· 0 citations
BACKGROUND
Pathological cardiac hypertrophy is a major risk factor for heart failure and is characterized by transcriptional and metabolic remodeling. Although chromatin accessibility is closely associated with transcriptional regulation, how accessibility changes relate to gene-expression and functional changes during...
Jian-Yun Xiong, Zhi-Yi Yin, Ke-Yue Hu et al.· Biochemical and Biophysical...· 0 citations
PKN2 loss drives fibroblast reprogramming and aberrant ECM remodelling, establishing PKN2 as an important regulator of pulmonary fibroblast homeostasis and tissue repair.
Catherine E. McMullan, Oscar A. Peña, P. Rajasekar et al.· bioRxiv· 0 citations
This study provides the first evidence demonstrating the functional role of Sema4f in cardiac fibroblast activation and fibrosis progression, and identifies a fibroblast-specific mechanism mediated by the Sema4f-actin cytoskeleton-YAP/TAZ axis, offering novel mechanistic insights into fibrosis regulation and revealing...
Jie Xu, Mengting He, Jiayao Liu et al.· Apoptosis· 0 citations
This work identifies the hepatic ChREBP-SURF4-ApoM axis as a critical pathway in cardiac remodeling, and induction of hepatic ApoM secretion constitutes a new promising approach for treating cardiac remodeling and heart failure.
Shuang Zhang, Zhen-zhen Zhang, Zi-Han Ma et al.· Circulation Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.